ArticleBioinformatics (Oxford, England)2025
H2GnnDTI: hierarchical heterogeneous graph neural networks for drug-target interaction prediction.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Graph-based drug-target interaction modeling: from representation learning to output-driven drug discovery.Briefings in bioinformatics · 2026Review
- Advanced drug-target interaction prediction using convolutional graph attention networks in expert systems.Molecular diversity · 2026Article
- CMMSCL-DPI: cross-modal multi-structural contrastive learning for predicting drug-protein interactions.BMC biology · 2026Article
- Graph neural networks for multi-scale gene-drug interaction modeling in cancer: applications, challenges, and therapeutic opportunities for breast cancer drug resistance.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
motivationIdentifying drug-target interactions (DTIs) is a crucial step in drug repurposing and drug discovery. The significant increase in demand and the expensive nature for experimentally identifying DTIs necessitate computational tools for automated prediction and comprehension of DTIs. Despite recent advancements, current methods fail to fully leverage the hierarchical information in DTIs.
resultsHere, we introduce H2GnnDTI, a novel two-level hierarchical heterogeneous graph learning model to predict DTIs, by integrating the structures of drugs and proteins via a low-level view GNN and a high-level view GNN. The hierarchical graph consists of high-level heterogeneous nodes representing drugs and proteins, connected by edges representing known DTIs. Each drug or protein node is further detailed in a low-level graph, where nodes represent molecules within each drug or amino acids within each protein, accompanied by their respective chemical descriptors. Two distinct low-level graph neural networks are first deployed to capture structural and chemical features specific to drugs and proteins from these low-level graphs. Subsequently, a high-level graph encoder (GE) is used to comprehensively capture and merge interactive features pertaining to drugs and proteins from the high-level graph. The high-level encoder incorporates a structure and attribute information fusion module designed to explicitly integrate representations acquired from both a feature encoder and a GE, facilitating consensus representation learning. Extensive experiments conducted on three benchmark datasets have shown that our proposed H2GnnDTI model consistently outperforms state-of-the-art deep learning methods. AVAILABILITY AND IMPLEMENTATION: The codes are freely available at https://github.com/LiminLi-xjtu/H2GnnDTI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.